High-grade B-cell lymphoma with and rearrangements is a rare lymphoma which has highly aggressive clinical manifestations. The reporting case is a 72-year-old female presented with lumbago and weakness in the lower limb due to a mass at T8-10 revealed by computed tomography (CT) scan. Histological feature of the lesion shows an abundant and diffuse large lymphoid cells infiltration. Immunophenotype meets with germ center B cell (GCB) lymphoma (Hans algorithm). and gene rearrangements are detected by fluorescence in situ hybridization (FISH). It's a rare and typical case of high-grade B-cell lymphoma with and rearrangements with uncommon clinical manifestation.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6965433 | PMC |
Publication Analysis
Top Keywords
Similar Publications
High-grade-B-cell lymphoma (HGBL) with MYC and BCL2 and/or BCL6 rearrangements (double hit [HGBL-DH] or triple hit [HGBL-TH]), or not otherwise specified (HGBL-NOS), are considered to be more aggressive diseases among large B-cell lymphomas (LBCL). CD19-targeting Chimeric Antigen Receptor (CAR) T-cells have changed the prognosis of chemoresistant LBCL. Clinical and pathological data of patients treated for relapsed/refractory LBCL or HGBL in third line or more, all characterized by FISH, were collected from the French DESCAR-T registry.
View Article and Find Full Text PDFCD19 CAR-T With Axicabtagene Ciloleucel in R/R Large B-Cell Lymphoma With/Without Prior Autologous Stem Cell Transplant.
Clin Lymphoma Myeloma Leuk
January 2025
Transplantation & Cellular Therapy Program, Division of Hematology/Oncology, Department of Internal Medicine, Greenebaum Comprehensive Cancer Center, University of Maryland Medical Center, University of Maryland School of Medicine, Baltimore, MD.
Background: Anti-CD19 CAR-T therapy has been a breakthrough in treatment of primary refractory or relapsed large B-cell lymphoma (r/r LBCL) and is poised to supplant previous second line of high dose chemotherapy and autologous stem cell transplantation (HDT/ASCT). However, in clinical practice, high risk patients with chemoimmunotherapy sensitive disease continue to receive salvage chemoimmunotherapy or cannot access CAR-T in a timely manner and thus may still proceed to HDT/ASCT. Little is known about clinical outcomes of CAR-T in patients who receive HDT/ASCT compared to those who are transplant-naïve.
View Article and Find Full Text PDFA Challenging Case of Myeloid Sarcoma Misdiagnosed as High-Grade B-Cell Lymphoma.
Ann Clin Lab Sci
November 2024
Department of Pathology, The University of Texas Health Science Center at Houston, McGovern Medical School, Houston, TX, USA.
A 46-year-old female presented with back pain associated with progressive bilateral lower extremity weakness and paresthesia. Imaging studies revealed a retroperitoneal mass with severe spinal compression. Histological sections showed blastoid cells with large nuclei, irregular membranes, fine chromatin, and prominent nucleoli.
View Article and Find Full Text PDFProlonged neurologic symptoms following immune effector cell-associated neurotoxicity syndrome in patients with large B cell lymphoma treated with chimeric antigen receptor-modified T cell therapy.
Transplant Cell Ther
January 2025
Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania.
Background: While immune effector cell-associated neurotoxicity syndrome (ICANS) is a well-defined adverse effect associated with chimeric antigen receptor-modified T cell (CAR-T) therapy, some patients develop prolonged neurologic symptoms. Few studies have examined characteristics and outcomes of patients who develop such symptoms.
Objective: To provide an analysis of patients who developed ICANS in a single-center cohort of patients with large B-cell lymphoma (LBCL) who received commercial CAR-T and compare characteristics and outcomes between patients with vs.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!